• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » The FDA and Big Pharma: A Turning Point

The FDA and Big Pharma: A Turning Point

March 1, 2005
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
1992 was a very big year in the history of the relationship between the FDA and the pharmaceutical industry. That year, Congress passed the Prescription Drug User Fee Act (PDUFA), allowing the FDA to charge pharmaceutical companies hundreds of thousands of dollars per drug for the drug approval process. (The total amount collected by the FDA from user fees for FY 2000 was approximately $137.7 million.) In a recent interview, Jerry Avorn, M.D., of Harvard Medical School and Ken Kaitin, M.D., of Tufts, indicated that "There is no question that there was a change in the culture of the FDA after the User Fee Act…. According to colleagues in the FDA, there is a sense now that the [pharmaceutical] industry is the client, effectively paying their salary, and that they need to do things that industry is comfortable with…. [Since 1992], the assumption is that every new drug application should be accepted unless there's something in the application that demands that it should be rejected." The interviewer, Dick Gordon, then asked, "So in 1992 did the FDA shift from working on behalf of the American people to working on behalf of the pharmaceutical industry?" "Well, that's what a lot of people who work at the FDA will tell you," was the response from the guests, as they cited drugs like dexfenfluramine (Redux) that were taken off the market within a year and that probably should never have been approved in the first place.

Sources:

  • http://www.theconnection.org/shows/2005/02/20050216_b_main.asp

  • http://www.bio.org/reg/pdufa/

General Psychiatry
Carlat 150x150
Daniel Carlat, MD

Treating Alcohol Use Disorder—A Fact Book (2023)

More from this author
www.thecarlatreport.com
Issue Date: March 1, 2005
SUBSCRIBE NOW
Table Of Contents
The FDA and Big Pharma: A Turning Point
Anecdote from the Field: I Was a Middle-Aged Drug Whore!
CME Bias: ACCME to the Rescue!
Jerome P. Kassirer, M.D., on Conflict of Interest in Medicine
Journal Articles as Marketing: Tricks of The Trade
How to Sniff Out Bias in CME Programs
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.